grant
First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers
Organization UNIVERSITY OF MARYLAND BALTIMORELocation BALTIMORE, UNITED STATESPosted 11 Dec 2023Deadline 30 Nov 2028
NIHUS FederalResearch GrantFY20251-Phosphatidylinositol 3-Kinase3' Untranslated Regions3'UTR3-D structure3-dimensional structure3D structure5' Untranslated Regions5'UTRAdoptedAffinityAnti-Cancer AgentsAntibodiesAntineoplastic AgentsAntineoplastic DrugsAntineoplasticsApoptosisApoptosis PathwayAssayAutoregulationBindingBioassayBiologicalBiological AssayBlood PlasmaBourneville DiseaseBourneville PhakomatosisBourneville syndromeBourneville-Brissaud diseaseBourneville-Pringle syndromeBypassCD152CD152 AntigenCD152 GeneCTLA 4CTLA-4 GeneCTLA4CTLA4 geneCTLA4-TMCancer Cell GrowthCancer ControlCancer Control ScienceCancer DrugCancer TreatmentCancersCell BodyCell FunctionCell Growth in NumberCell MultiplicationCell PhysiologyCell ProcessCell ProliferationCellsCellular FunctionCellular PhysiologyCellular ProcessCellular ProliferationCellular biologyCentrocytic Small-Cell LymphomaCheckpoint inhibitorChemicalsClinicClinicalComputer AssistedCytotoxic T-Lymphocyte Protein 4Cytotoxic T-Lymphocyte-Associated Antigen 4Cytotoxic T-Lymphocyte-Associated Protein 4Cytotoxic T-Lymphocyte-Associated Serine Esterase-4DNA Damage RepairDNA RepairDataDevelopmentDoseDown-RegulationDrug CombinationsDrug DesignDrugsEIF-4GEIF4GEffectivenessEpiloiaEukaryotic Initiation Factor-4GEukaryotic Peptide Initiation Factor-4GEukaryotic Translation Initiation Factor 4 gammaEukaryotic-Translation Initiation Factor 4GExhibitsFK506 Binding Protein 12-Rapamycin Associated Protein 1FKBP12 Rapamycin Complex Associated Protein 1FRAP1FRAP1 geneFRAP2FeedbackGeneralized GrowthGenerationsGoalsGrawitz TumorGrowthHeterogeneous-Nuclear RibonucleoproteinsHeterograftHeterologous TransplantationHomeostasisHumanHypernephroid CarcinomaHypernephromaImmuneImmune EvasionImmune TargetingImmune checkpoint inhibitorImmune responseImmunesImmunologistIn VitroInformoferIntermediary MetabolismLeadLymphoma, Lymphocytic, Diffuse, Poorly-DifferentiatedMalignant CellMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMantle Cell LymphomaMantle-Zone LymphomaMechanistic Target of RapamycinMedicationMedicinal ChemistryMedicineMessenger RNAMetabolic ProcessesMetabolismMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMethodsMiceMice MammalsModelingModern ManModificationMolecular InteractionMurineMusNeoplasm MetastasisNeoplastic Disease Chemotherapeutic AgentsNephroid CarcinomaNon-Polyadenylated RNANormal CellNormal TissueNormal tissue morphologyOncologistPI-3 KinasePI3-KinasePI3CGPI3KGammaPI3kPIK3PIK3CGPIK3CG genePathway interactionsPatientsPb elementPeptide Initiation Factor EIF-4GPharmaceutic ChemistryPharmaceutical ChemistryPharmaceutical PreparationsPhosphatidylinositol 3-KinasePhosphatidylinositol-3-OH KinasePhosphoinositide 3-HydroxykinasePhysiological HomeostasisPlasmaPlasma SerumPringle diseaseProgrammed Cell DeathProliferatingPropertyProtein BiosynthesisProtein InhibitionProteinsPtdIns 3-KinasePutative RNA-Binding RegionRAFT1RNARNA BindingRNA Binding DomainRNA Gene ProductsRNA Polymerase InhibitorRNA Recognition MotifRNA and protein interactionRNA boundRNA-Binding ProteinsRNA-Protein InteractionRNP DomainRNP MotifRNP-1 SignatureRegulatory PathwayRenal AdenocarcinomaRenal Cell AdenocarcinomaRenal Cell CancerRenal Cell CarcinomaReporterResistanceReticuloendothelial System, Serum, PlasmaReverse Transcriptase InhibitorsRibonucleic AcidRibonucleoproteinsRibosomal Peptide BiosynthesisRibosomal Protein BiosynthesisRibosomal Protein SynthesisRoleScheduleSecondary NeoplasmSecondary TumorSolid NeoplasmSolid TumorSolubilitySpecificityStressStructural BiologistSubcellular ProcessTherapeuticTherapeutic AgentsTherapeutic IndexTissue GrowthToxic effectToxicitiesTranscriptTranslation InitiationTranslational InhibitionTranslational RepressionTranslationsTuberous SclerosisTumor-Specific Treatment AgentsType I Phosphatidylinositol KinaseType III Phosphoinositide 3-KinaseUnscheduled DNA SynthesisViralXenograftXenograft ModelXenograft procedureXenotransplantationadenoma sebaceumanalogangiogenesisanti-cancer druganti-cancer therapybiologiccancer cellcancer drug resistancecancer metastasiscancer progressioncancer therapycancer typecancer-directed therapycell biologycerebral sclerosischemotherapycomputer aidedcytotoxic T-lymphocyte antigen 4designdesigningdevelop drug resistancedevelopmentaldrug resistance developmentdrug/agentefficacy testingepiploiaflexibilityflexibleheavy metal Pbheavy metal leadhereditary multiple system hamartomatosishnRNPhost responseimmune check pointimmune check point inhibitorimmune checkpointimmune evasiveimmune system responseimmunecheckpointimmunoresponseimprovedin vivoinhibit proteininhibit proteinsinhibitorinnovateinnovationinnovativekidney adenocarcinomamRNAmRNA Leader SequencesmTORmalignancymammalian target of rapamycinmultidisciplinaryneoplasm progressionneoplasm/cancerneoplastic progressionneurinomatosis centralisneuromatosis universalisneurospongioblastosis diffusanovelontogenyoverexpressoverexpressionpathwayphacomatosisprecision medicineprecision-based medicinepreventpreventingprotein inhibitionsprotein synthesisrational designresistance to cancer drugsresistantresistant to cancer drugsresponsescaffoldscaffoldingsclerosis tuberosasmall molecular inhibitorsmall moleculesmall molecule inhibitorsocial rolespongioblastosis circumscriptastructural biologytargeted cancer therapythree dimensional structuretranslationtuberose sclerosistuberous sclerosis complextumortumor cell metastasistumor growthtumor progressionvirtualxeno-transplantxeno-transplantationxenograft transplant modelxenotransplant model
Description preview
PROJECT SUMMARY
Therapeutic approaches in cancer therapies have evolved from the use of highly toxic chemotherapy agents to
precision medicine with well-defined targets and minimal toxicities. While precision medicine is highly
desirable, its effectiveness depends on the presence of the activating agents and typically target a single
pathway which…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click